| RS281864956 |
GNPTG
|
Health Risk |
Pathogenic |
GNPTG-mucolipidosis, GNPTG-mucolipidosis |
| RS281864961 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864962 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864963 |
GNPTAB
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864964 |
GNPTAB
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucolipidosis type II, Mucolipidosis |
| RS281864969 |
GNPTAB
|
Health Risk |
Pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS281864970 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS281864973 |
GNPTAB
|
Health Risk |
Pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS281864976 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis |
| RS281864980 |
GNPTAB
|
Health Risk |
Pathogenic/Likely pathogenic |
Pseudo-Hurler polydystrophy, Legg-Calve-Perthes disease |
| RS281864981 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864982 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864983 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864984 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864991 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281864992 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864996 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864998 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281864999 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis |
| RS281865001 |
GNPTAB
|
Health Risk |
Pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS281865004 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS281865007 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281865009 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281865012 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865017 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281865018 |
GNPTAB
|
Health Risk |
Pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS281865019 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis |
| RS281865022 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281865023 |
GNPTAB
|
Health Risk |
Pathogenic/Likely pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281865024 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Pseudo-Hurler polydystrophy |
| RS281865025 |
GNPTAB
|
Health Risk |
Likely pathogenic |
Mucolipidosis III alpha/beta, atypical |
| RS281865026 |
GNPTAB
|
Health Risk |
Pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS281865027 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865028 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865029 |
GNPTAB
|
Health Risk |
Pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS281865030 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865031 |
GNPTAB
|
Health Risk |
Pathogenic |
Pseudo-Hurler polydystrophy, Mucolipidosis type II |
| RS281865032 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865033 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865035 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865036 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865037 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucopolysaccharidosis, MPS-III-A |
| RS281865038 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865039 |
GNPTAB
|
Health Risk |
Pathogenic |
Mucolipidosis type II, Mucolipidosis type II |
| RS281865060 |
GDAP1
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 4A, Charcot-Marie-Tooth disease |
| RS281865061 |
PRX
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 4F, Dejerine-Sottas disease |
| RS281865065 |
FGD4
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 4H, Charcot-Marie-Tooth disease |
| RS281865067 |
CHRNA4
|
Health Risk |
Pathogenic |
Autosomal dominant nocturnal frontal lobe epilepsy 1, Autosomal dominant nocturnal frontal lobe epilepsy 1 |
| RS281865070 |
CHRNB2
|
Health Risk |
Pathogenic/Likely pathogenic |
Autosomal dominant nocturnal frontal lobe epilepsy, Autosomal dominant nocturnal frontal lobe epilepsy |
| RS281865075 |
HPS1
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 1, Hermansky-Pudlak syndrome |
| RS281865076 |
HPS1
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 1, Hermansky-Pudlak syndrome |
| RS281865077 |
HPS1
|
Health Risk |
Pathogenic/Likely pathogenic |
Hermansky-Pudlak syndrome 1, Hermansky-Pudlak syndrome |
| RS281865079 |
HPS1
|
Health Risk |
Pathogenic |
— |
| RS281865080 |
HPS1
|
Health Risk |
Pathogenic/Likely pathogenic |
Hermansky-Pudlak syndrome 1, Hermansky-Pudlak syndrome |
| RS281865081 |
HPS1
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 1, Hermansky-Pudlak syndrome |
| RS281865082 |
HPS1
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 1, Hermansky-Pudlak syndrome |
| RS281865084 |
HPS1
|
Health Risk |
Pathogenic/Likely pathogenic |
Hermansky-Pudlak syndrome 1, Hermansky-Pudlak syndrome |
| RS281865086 |
HPS1
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome, Hermansky-Pudlak syndrome 1 |
| RS281865088 |
HPS1
|
Health Risk |
Pathogenic/Likely pathogenic |
Hermansky-Pudlak syndrome, Hermansky-Pudlak syndrome 1 |
| RS281865090 |
HPS1
|
Health Risk |
Pathogenic/Likely pathogenic |
Hermansky-Pudlak syndrome, Hermansky-Pudlak syndrome 1 |
| RS281865093 |
HPS3
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 3, Hermansky-Pudlak syndrome 3 |
| RS281865095 |
HPS3
|
Health Risk |
Pathogenic/Likely pathogenic |
Hermansky-Pudlak syndrome 3, Hermansky-Pudlak syndrome 3 |
| RS281865097 |
HPS4
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 4, Hermansky-Pudlak syndrome 4 |
| RS281865098 |
HPS4
|
Health Risk |
Conflicting classifications of pathogenicity |
Hermansky-Pudlak syndrome 4, Hermansky-Pudlak syndrome 4 |
| RS281865100 |
HPS4
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 4, Hermansky-Pudlak syndrome 4 |
| RS281865101 |
HPS5
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 5, Hermansky-Pudlak syndrome 5 |
| RS281865102 |
HPS5
|
Health Risk |
Likely pathogenic |
— |
| RS281865103 |
HPS5
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 5, Hermansky-Pudlak syndrome 5 |
| RS281865104 |
HPS5
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 5, Hermansky-Pudlak syndrome 5 |
| RS281865105 |
HPS5
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 5, Hermansky-Pudlak syndrome 5 |
| RS281865107 |
HPS6
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 6, Hermansky-Pudlak syndrome 6 |
| RS281865108 |
HPS6
|
Health Risk |
Conflicting classifications of pathogenicity |
Hermansky-Pudlak syndrome 6, Hermansky-Pudlak syndrome |
| RS281865110 |
HPS6
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 6, Hermansky-Pudlak syndrome 6 |
| RS281865112 |
HPS6
|
Health Risk |
Pathogenic/Likely pathogenic |
Hermansky-Pudlak syndrome 6, Hermansky-Pudlak syndrome 6 |
| RS281865113 |
HPS6
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 6, Hermansky-Pudlak syndrome 6 |
| RS281865114 |
HPS6
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 6, Hermansky-Pudlak syndrome 6 |
| RS281865115 |
BLOC1S3
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 8, Hermansky-Pudlak syndrome 8 |
| RS281865116 |
BLOC1S3
|
Health Risk |
Pathogenic |
Hermansky-Pudlak syndrome 8, Hermansky-Pudlak syndrome 8 |
| RS281865117 |
SACS
|
Health Risk |
Pathogenic |
Charlevoix-Saguenay spastic ataxia, Spastic paraplegia |
| RS281865118 |
SACS
|
Health Risk |
Pathogenic |
Charlevoix-Saguenay spastic ataxia, Spastic paraplegia |
| RS281865119 |
SACS
|
Health Risk |
Conflicting classifications of pathogenicity |
Charlevoix-Saguenay spastic ataxia, Spastic paraplegia |
| RS281865120 |
SACS
|
Health Risk |
Pathogenic/Likely pathogenic |
Charlevoix-Saguenay spastic ataxia, Spastic paraplegia |
| RS281865121 |
MPZ
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 1B, Dejerine-Sottas disease |
| RS281865123 |
MPZ
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 1B, Charcot-Marie-Tooth disease |
| RS281865124 |
MPZ
|
Health Risk |
Pathogenic/Likely pathogenic |
Charcot-Marie-Tooth disease type 1B, Charcot-Marie-Tooth disease |
| RS281865125 |
MPZ
|
Health Risk |
Pathogenic/Likely pathogenic |
Charcot-Marie-Tooth disease type 1B, Charcot-Marie-Tooth disease |
| RS281865127 |
MPZ
|
Health Risk |
Conflicting classifications of pathogenicity |
Charcot-Marie-Tooth disease type 1B, Charcot-Marie-Tooth disease |
| RS281865128 |
MPZ
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 1B, Charcot-Marie-Tooth disease |
| RS281865134 |
LITAF
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 1C, Charcot-Marie-Tooth disease |
| RS281865135 |
LITAF
|
Health Risk |
Likely pathogenic |
Charcot-Marie-Tooth disease type 1C, Charcot-Marie-Tooth disease |
| RS281865136 |
EGR2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 1D, Charcot-Marie-Tooth disease |
| RS281865137 |
EGR2
|
Health Risk |
Pathogenic |
Charcot-Marie-Tooth disease type 1D, Charcot-Marie-Tooth disease |
| RS281865141 |
CRYAB
|
Health Risk |
Pathogenic |
Myofibrillar myopathy 2, Myofibrillar myopathy 2 |
| RS281865142 |
CRYAB
|
Health Risk |
Conflicting classifications of pathogenicity |
Myofibrillar myopathy 2, Dilated cardiomyopathy 1II |
| RS281865144 |
ZNF469
|
Health Risk |
Pathogenic |
Keratoconus 1, Keratoconus 1 |
| RS281865145 |
ZNF469
|
Health Risk |
Conflicting classifications of pathogenicity |
Keratoconus 1, Cardiovascular phenotype |
| RS281865149 |
ZNF469
|
Health Risk |
Conflicting classifications of pathogenicity |
Keratoconus 1, Ehlers-Danlos syndrome |
| RS281865150 |
ZNF469
|
Health Risk |
Pathogenic |
Keratoconus 1, Keratoconus 1 |
| RS281865151 |
ZNF469
|
Health Risk |
Conflicting classifications of pathogenicity |
Keratoconus 1, Brittle cornea syndrome 1 |
| RS281865152 |
ZNF469
|
Health Risk |
Conflicting classifications of pathogenicity |
Keratoconus 1, Cardiovascular phenotype |